Out-of-pocket costs for brand-name medications for neurological disorders increased significantly over a 9-year period, with the largest hikes in MS drugs, new research shows.
In the United States, out-of-pocket costs of brand-name medications for neurological disorders increased significantly from 2012 to 2021, with the largest hikes in multiple sclerosis drugs, new analysis shows.
“What we’re seeing is an increased and disproportionate burden of these costs to the patients, but not to the system at large,” study author Amanda Gusovsky, PhD, MPH, of Ohio State University in Columbus, toldShe added that OOP costs for MS drugs have steadily increased over the past 20 years, suggesting that current efforts to control these rising costs for MS medications have not been very effective.
OOP costs for the PN medication duloxetine dropped by 80% from an average of $231 in 2012 to $46 in 2021 after the generic version was introduced in 2013. Similarly, OOP costs for pregabalin decreased by 73% — from $204 in 2012 to $56 in 2020 after the introduction of the generic version in 2019. The investigators noted that overall trends in total costs largely mirrored those of OOP costs, with few exceptions. Total costs for MS medications rose by an average of 80% over the study period, though they began to level off for some drugs toward 2021. Glatiramer saw a moderate decline in total costs from 2017 to 2021, while rasagiline peaked in 2016 at $6064 and subsequently decreased to $1798 by 2021.Several drug cost–reduction strategies are already underway, said Bruce H.
Multiple Sclerosis MS - Multiple Sclerosis Generics Generic Drug Generic Medication Medicare Drug Costs Drug Cost Medication Costs Drug Price Drug Pricing Medication Price Medication Pricing Epilepsy Seizure Disorder Parkinson's Disease Parkinson Disease Parkinsons Parkinson Parkinson Disease (PD) Dementia Peripheral Neuropathy Biologic Therapy Biologics
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Huge direct costs and incalculable indirect costs stem from psychopathic damage.The cost of psychopathic damage is exorbitant and largely incalculable, although estimates of direct costs in the U.S. approach $1.6 trillion annually.
Read more »
Most Patients Can Keep Using GLP-1 Weight Loss Meds Before SurgeriesA new guidance issued jointly by groups representing U.S. surgeons, anesthesiologists and gastroenterologists affirms that most people taking popular GLP-1 weight-loss meds can keep taking them in the weeks before a surgery.
Read more »
Mixing meds: What not to take with morning beveragesMore than 131 million adults in the U.S. take a prescription drug. But taking these medicines with popular beverages, like coffee and juice, can be dangerous.
Read more »
Too Many Meds: 'Polypharmacy' Can Really Harm Alzheimer's PatientsAlzheimer’s disease patients prescribed fistfuls of daily drugs are at greater risk of harm, a new study warns.
Read more »
GLP-1 Weight-Loss Meds Won't Raise Teens' Suicide Risk, May Even Lower ItAs with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide and suicidal thoughts.
Read more »
How your skin tone could affect your medsSkin pigmentation may act as a 'sponge' for some medications, potentially influencing the speed with which active drugs reach their intended targets, a pair of scientists report.
Read more »